A6 | Neutralizing antibody induction associated with a germline immunoglobulin gene polymorphism in rhesus macaques after neutralization-resistant SIVsmE543-3 infection | E-poster | Humoral immunity (including broadly neutralizing antibodies) |
B27 | HIV immune reconstitution inflammatory response syndrome and the risk of adverse pregnancy-fetal outcomes among ART naïve women aged 20-49 years in selected public hospitals, Nairobi, Kenya | On-demand oral abstract session | Immune reconstitution disorders and immune reconstitution inflammatory syndrome |
B80 | Robust SARS-CoV-2-specific serological and functional t-cell immunity in PLWHIV | On-demand oral abstract session | Immune responses against SARS-CoV2 in PLWHIV |
A30 | Dysregulation of IFN-γ, TNF-a, IL-12 and IL-18 secretion in newly diagnosed individuals with HIV/TB co-infection | E-poster | Immune responses during acute HIV infection |
B45 | New generation of HYBRID CAR-T cells efficiently kill HIV infected cells and neutralize cell-free virus | On-demand oral abstract session | Immune-based therapy trials |
A22 | STAT modulation as strategy to improve NK cell cytotoxicity against HIV and cancer | On-demand oral abstract session | Immunotherapy: Immune-Modifying Agents |
A22 | Dual IL-10 and PD-1 blockade in SIVmac239 infected macaques promotes sustained virologic control in absence of ART | Oral abstract session with live Q&A | Immunotherapy: Immune-Modifying Agents |
A21 | Defining CTL immunotherapy candidates against replication-competent and defective HIV | On-demand oral abstract session | Immunotherapy: Vaccines and antibodies |
A21 | The balance of mucosal CD4 T cells prior to infection is associated with control of virus replication after therapeutic vaccination in SIV-infected rhesus macaques | On-demand oral abstract session | Immunotherapy: Vaccines and antibodies |
D2 | Improving health equity and ending the HIV epidemic in the United States: a distributional cost-effectiveness analysis in six cities | On-demand oral abstract session | Impact evaluation of differentiated service delivery |